FRESH FROM ASCO:Alpharadin Significantly Improves Overall Survival in Phase III Trial in Patients. Good news for patients with castration-resistant prostate cancer that has spread to the bone.
News Release ,June 6, 2011. Alpharadin Significantly Improves Overall Survival in Phase III Trial in Patients with Castration-Resistant Prostate Cancer That Has Spread to the